Retatrutide vs. Tirzepatide vs. Semaglutide: No Head-to-Head Trial Yet
Audio Brief
Show transcript
A new investigational drug is pushing human weight loss so high that, as Dr. Gabrielle Lyon says twice, she frankly does not know what she thinks about it. On her show, released on November 5, 2026, Dr. Lyon examines the Phase 3 clinical trial results for a medication called retatrutide. By the end of this summary, you will learn how this triple hormone drug works and how to protect your muscle during rapid weight loss.
How targeting three hormones unlocks a new way to burn fat. Retatrutide is a triple hormone agonist that combines two gut hormone targets, GLP 1 and GIP, which reduce appetite, slow digestion, and boost insulin, with a third hormone called glucagon. Stimulating all three receptors together increases how much fat the body mobilizes and burns, and although the glucagon part also boosted energy burned in obese mice, Dr. Lyon cautions that mice are not humans and this specific effect is not yet proven in people.
These three pathways drive pharmacological weight loss that matches or beats bariatric surgery. In an 80 week trial of over 2,300 non diabetic adults with obesity, people on the highest dose lost between 25 and 28 percent of their weight without any prescribed calorie restriction, and roughly 30 percent in a two year extension.
Losing that much weight triggers deep health shifts across the entire body. At the highest dose, shedding an average of 62 pounds cut systemic inflammation by more than 60 percent, dropped fasting insulin by over half, and normalized blood sugar for the large majority of prediabetic participants. Dr. Lyon notes it is not proven whether the drug causes these improvements directly or if they simply result from losing a quarter of your body weight.
However, rapid weight loss comes with a hidden cost to your muscle and bone. Because this Phase 3 trial did not measure body composition in detail, clinicians look to an earlier Phase 2 scan study in people with type 2 diabetes, where lean mass fell by up to 14 pounds, making up 30 to 40 percent of the total weight lost.
You can prevent that muscle loss by giving your body the right physical signals. Dr. Lyon points out that while no study has combined retatrutide with lifting and high protein yet, a four week trial by Longland and colleagues put active young men in a 40 percent calorie deficit while lifting weights six days a week, and they actually gained fat free mass while losing fat. To protect the quality of your own weight loss, do resistance training two to three times a week and eat 1.2 to 1.6 grams of protein per kilogram of body weight.
High potency also brings stomach side effects and the risk of losing too much weight. At the top dose, about two in five participants felt nausea, and over 5 percent actually stopped the drug because their weight loss was considered excessive or already sufficient. Work with a clinician to stay on the lowest dose needed to reach your health goals.
Finally, understand why you cannot get a prescription for this drug today. Even with Phase 3 trials published, retatrutide awaits approval by the Food and Drug Administration, or FDA, and remains an unapproved investigational medication that Dr. Lyon does not take or prescribe.
When massive weight loss becomes possible through medication, the real priority shifts from simply dropping pounds to protecting your lean muscle and staying safe. While retatrutide awaits FDA approval, avoid buying it on the internet as an unregulated research chemical for personal use.
Episode Overview
- Dr. Gabrielle Lyon breaks down the Phase 3 TRIUMPH-1 clinical trial results for the investigational weight-loss drug retatrutide and explains how to protect lean muscle mass during rapid weight loss.
- Unlike existing medications that target one or two hormonal pathways, retatrutide is a triple hormone agonist that activates GLP-1, GIP, and glucagon receptors, driving weight loss that rivals or exceeds bariatric surgery.
- The episode examines the trial data across different dosing tiers, highlighting improvements in cardiometabolic markers, prediabetes, sleep apnea, and knee osteoarthritis alongside gastrointestinal side effects.
- Because massive weight loss is now pharmacologically achievable, the primary clinical challenge shifts from simply losing weight to preserving fat-free mass through nutrition and exercise.
Key Concepts
- Triple Hormone Agonism: While semaglutide targets one pathway (GLP-1) and tirzepatide targets two (GLP-1 and GIP), retatrutide targets three receptors by adding glucagon. GLP-1 reduces appetite, slows gastric emptying, and increases insulin secretion, while GIP complements these effects in the brain and pancreas. Although glucagon raises glucose during fasting, stimulating its receptor alongside GLP-1 and GIP increases fat oxidation and mobilization. In pre-clinical mouse models, the glucagon component also increased energy expenditure, though Dr. Lyon cautions that obese mice are not humans and this specific mechanism is not yet proven in humans.
- Unprecedented Pharmacological Weight Loss: In the 80-week TRIUMPH-1 Phase 3 trial (enrolling 2,339 non-diabetic adults with obesity at an average baseline weight of 248 lbs and a BMI around 40), participants received healthy lifestyle counseling but no prescribed calorie restriction. Weight loss scaled by weekly dose: 2.2% to 4% for placebo, 17% to 19% at 4 mg, 23.7% to 25.9% at 9 mg, and 25% to 28% at 12 mg (with an extension phase showing roughly 30% mean weight loss at 104 weeks). This outperforms historical benchmarks like semaglutide (about 15% in STEP 1, or 14% vs. tirzepatide's 20% in the 72-week SURMOUNT-5 head-to-head trial), tirzepatide (about 21% in SURMOUNT-1), and averages for bariatric surgery (15% to 30%). Dr. Lyon notes that there is not yet a head-to-head clinical trial comparing retatrutide to tirzepatide, and she twice states, "Frankly, I don't know what I think" about medications pushing weight loss percentages this high.
- Cardiometabolic and Disease Remission: At the 12 mg dose, losing an average of 62 lbs produced profound systemic health shifts: waist circumference dropped by 8.5 inches, systolic blood pressure fell by 10 mmHg, triglycerides dropped by 38%, fasting insulin fell by 55%, and C-reactive protein (CRP, a marker of systemic inflammation) fell by 63%. Furthermore, the large majority of prediabetic participants achieved normal glucose levels, while sub-studies of 547 participants with knee osteoarthritis and 243 with obstructive sleep apnea showed substantial reductions in knee pain scores and apneas per hour. Dr. Lyon notes it is not proven whether the drug drives these marker improvements directly or if they are primarily the physiological result of losing 25% of body weight.
- The Lean Mass Loss Challenge: Standard dietary weight loss and obesity pharmacotherapies typically result in 20% to 40% of total weight loss coming from fat-free mass (which includes skeletal muscle, bone, and organs). Because TRIUMPH-1 did not include a detailed body composition analysis, clinicians must look to a Phase 2 DEXA sub-study conducted in people with type 2 diabetes. That data showed lean mass fell by up to 12.5% (roughly 6.5 kg or 14 lbs) at the 8 mg dose, meaning 30% to 40% of total weight lost came from lean tissue.
- Muscle Preservation in a Caloric Deficit: Losing skeletal muscle during rapid weight loss is preventable with the right physiological stimuli, though Dr. Lyon points out no study has yet combined retatrutide with resistance training and high-protein intake. In a study of nearly 1,400 people with obesity using a protein-based, very low-calorie approach over 3 months, the fraction of lean mass loss stayed relatively low. Furthermore, a study by Longland et al. put recreationally active young men without obesity on a 40% energy deficit for 4 weeks while lifting weights 6 days a week; groups eating 1.2 g/kg and 2.4 g/kg of protein both gained fat-free mass during the deficit, with the higher-protein group gaining significantly more lean mass and losing more fat.
- Adverse Events and Excessive Weight Loss: Side effects in TRIUMPH-1 occurred mostly during dose escalation. At the highest 12 mg dose, 42% of participants experienced nausea, 32% had diarrhea, 26% had constipation, and 25% experienced vomiting. Remarkably, the drug was so potent that some participants had to stop or reduce treatment because they lost too much weight.
- Clinical Trial Phases and Regulatory Status: Clinical trials progress from Phase 1 (early human safety and dosing) to Phase 2 (testing efficacy for the target condition and refining dose and safety) to Phase 3 (large-scale tests in hundreds or thousands of people to confirm efficacy and safety for FDA approval). Even with TRIUMPH-1 and companion Phase 3 diabetic trials (TRIUMPH-2 and TRANSCEND-T2D-1) published, retatrutide remains an investigational medication that is not FDA-approved. Dr. Lyon notes that she treats patients using semaglutide and tirzepatide at her practice, Strong Medical, and that she does not take or prescribe retatrutide.
Quotes
- At 3:41 - "What sets Reta apart from the currently approved GLP-1 medications like semaglutide and tirzepatide is that it is a triple hormone agonist, meaning it is targeting three different hormone receptors: GLP-1, GIP, and glucagon." - Explaining the unique pharmacological mechanism of retatrutide compared to first- and second-generation medications.
- At 5:10 - "So at the highest dose of retatrutide, people lost an average of 25% of their body weight over 80 weeks. More than one-third of people taking the highest dose lost 30% of their body weight, and about one in five lost at least 35%." - Highlighting the headline weight-loss results from the TRIUMPH-1 trial.
- At 11:56 - "Out of a group of people with moderate to severe obesity, using Reta for 18 months caused more than half to no longer be classified as obese, and one in four to be classified as a normal weight based on BMI." - Demonstrating how the 12 mg dose shifted participant BMI from a baseline average of 40 down below 30 and 25.
- At 20:01 - "And the evidence here is consistent: resistance training two or three times per week and adequate protein intake, on the order of 1.2 to 1.6 grams per kg, are the two levers that preserve lean mass during weight loss." - Identifying the specific lifestyle interventions required to prevent muscle loss during caloric restriction.
- At 26:37 - "Some participants reduced or stopped treatment because they had lost too much weight. And at the highest dose, 5.3% discontinued their retatrutide because their weight loss was considered excessive or already sufficient." - Revealing an unprecedented outcome in obesity medicine where patients stopped a trial drug due to losing too much weight.
Takeaways
- Do not purchase retatrutide online: Because retatrutide is still an investigational drug awaiting FDA approval, avoid buying it on the internet as an unregulated "research chemical" for personal use.
- Pair weight-loss medications with protein and lifting: To protect the quality of your weight loss and prevent the standard 20% to 40% loss of lean tissue, perform resistance training 2 to 3 times per week and consume 1.2 to 1.6 grams of protein per kilogram of body weight.
- Use the lowest effective medication dose: Because gastrointestinal side effects spike during dose escalation and higher doses can drive excessive weight and lean tissue loss, work with a clinician to stay on the lowest dose needed to achieve health goals rather than automatically escalating to the maximum dose.